Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007
Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
A Modified Peripheral Neuropathy Scale: The Overall Neuropathy Limitations Scale
JNNP 77:973-976,899, Graham,R.C. &Hughes,R.A.C., 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Relative Contributions of Brain and Cervical Cord Pathology to Multiple Sclerosis Disability: a Study with Magnetisation Transfer Ratio Histogram Analysis
JNNP 69:723-727, Rovaris,M.,et al, 2000
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Development & Prelimin Validation of a Pain Measure Spec to Neuropathic Pain:Neuropathic Pain Scale
Neurol 48:332-338, Galer,B.S.&Jensen,M.P., 1997
Doctors & Pts Don't Agree:Cross Sectional Study of Pts' & Doctors'Perceptions & Assessments of Disability in MS
BMJ 314:1580-1583, Rothwell,P.M.,et al, 1997
The Impact of Inpatient Rehabilitation on Progressive Multiple Sclerosis
Ann Neurol 42:236-244, Freeman,J.A.,et al, 1997
Correlation Between Changes in Disability and T2-Weighted Brain MRI Activity in Multiple Sclerosis:A Follow-up Study
Neurol 45:255-260, Filippi,M.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Interferon Beta-1b is Effective in Relapsing-Remitting MS
Clinical Results of a Placebo-Controlled Trial, IFNB MS Study Grp, Neurol 43:655-661, 64193., , 1993
Interferon Beta-1b is Effective in Relapsing Remitting MS, MRI Analysis Results of Placebo-Control Trial
Neurol 43:662-667, 6411993., Paty,D.W.,et al, 1993
Quality of Life in Multiple Sclerosis, Comparison with Inflam Bowel Dis & Rheumatic Arthritis
Arch Neurol 49:1237-1242, Rudick,R.A.,et al, 1992
The Disability Status Scale for Multiple Sclerosis:Apologia Pro DSS Sau
Neurol 39:291-302, Kurtzke,J.F., 1989
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989
Interrater Reliability in Assessing Functional Systems and Disability on the Kurtzke Scale in Multiple Sclerosis
Arch Neurol 45:746-748, Amato,M.P.,et al, 1988
Scales for Rating Impairment in Multiple Sclerosis:A Critique
Neurol 38:1793-1798, Willoughby,E.W.&Paty,D.W., 1988